Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RGNX |
---|---|---|
09:32 ET | 8218 | 14.09 |
09:34 ET | 200 | 14.18 |
09:36 ET | 192 | 14.2799 |
09:38 ET | 100 | 14.1 |
09:43 ET | 2961 | 14.14 |
09:45 ET | 4106 | 14.15 |
09:48 ET | 300 | 14.1675 |
09:50 ET | 625 | 14.1275 |
09:52 ET | 300 | 14.09 |
09:54 ET | 300 | 14.1675 |
09:56 ET | 3947 | 14.1 |
09:57 ET | 100 | 14.115 |
10:01 ET | 490 | 14.16 |
10:03 ET | 244 | 14.15 |
10:08 ET | 100 | 14.13 |
10:10 ET | 100 | 14.105 |
10:12 ET | 300 | 14.185 |
10:14 ET | 100 | 14.22 |
10:19 ET | 200 | 14.35 |
10:21 ET | 100 | 14.39 |
10:24 ET | 100 | 14.43 |
10:28 ET | 100 | 14.35 |
10:32 ET | 505 | 14.385 |
10:33 ET | 1554 | 14.355 |
10:35 ET | 856 | 14.35 |
10:37 ET | 400 | 14.29 |
10:39 ET | 236 | 14.36 |
10:42 ET | 500 | 14.26 |
10:44 ET | 200 | 14.26 |
10:46 ET | 200 | 14.27 |
10:50 ET | 1443 | 14.26 |
10:55 ET | 400 | 14.25 |
10:57 ET | 1600 | 14.24 |
11:00 ET | 200 | 14.19 |
11:06 ET | 100 | 14.1975 |
11:09 ET | 300 | 14.19 |
11:13 ET | 100 | 14.19 |
11:15 ET | 1100 | 14.2 |
11:18 ET | 1312 | 14.16 |
11:24 ET | 500 | 14.22 |
11:26 ET | 1600 | 14.21 |
11:27 ET | 600 | 14.22 |
11:31 ET | 657 | 14.26 |
11:33 ET | 110 | 14.28 |
11:36 ET | 840 | 14.25 |
11:38 ET | 191 | 14.2733 |
11:42 ET | 500 | 14.22 |
11:47 ET | 500 | 14.26 |
11:49 ET | 400 | 14.245 |
11:51 ET | 200 | 14.225 |
11:54 ET | 1205 | 14.25 |
11:56 ET | 200 | 14.24 |
12:00 ET | 100 | 14.245 |
12:02 ET | 100 | 14.245 |
12:03 ET | 200 | 14.25 |
12:05 ET | 3708 | 14.355 |
12:09 ET | 1929 | 14.31 |
12:12 ET | 500 | 14.3 |
12:14 ET | 100 | 14.33 |
12:18 ET | 600 | 14.29 |
12:20 ET | 200 | 14.285 |
12:21 ET | 1100 | 14.265 |
12:23 ET | 900 | 14.265 |
12:27 ET | 790 | 14.29 |
12:30 ET | 795 | 14.28 |
12:32 ET | 1000 | 14.3 |
12:34 ET | 300 | 14.33 |
12:36 ET | 700 | 14.33 |
12:38 ET | 100 | 14.335 |
12:39 ET | 1096 | 14.345 |
12:41 ET | 100 | 14.345 |
12:45 ET | 525 | 14.38 |
12:50 ET | 942 | 14.385 |
12:54 ET | 500 | 14.44 |
12:56 ET | 9991 | 14.47 |
12:57 ET | 1199 | 14.45 |
12:59 ET | 4900 | 14.47 |
01:01 ET | 1174 | 14.4325 |
01:03 ET | 100 | 14.38 |
01:06 ET | 232 | 14.4029 |
01:08 ET | 1200 | 14.41 |
01:10 ET | 500 | 14.4 |
01:14 ET | 214 | 14.43 |
01:19 ET | 300 | 14.41 |
01:21 ET | 200 | 14.41 |
01:24 ET | 1800 | 14.395 |
01:26 ET | 971 | 14.4 |
01:28 ET | 400 | 14.42 |
01:30 ET | 100 | 14.43 |
01:33 ET | 400 | 14.42 |
01:37 ET | 714 | 14.41 |
01:39 ET | 512 | 14.4288 |
01:42 ET | 918 | 14.3906 |
01:44 ET | 422 | 14.39 |
01:53 ET | 300 | 14.38 |
01:57 ET | 400 | 14.35 |
02:00 ET | 223 | 14.38 |
02:08 ET | 707 | 14.32 |
02:15 ET | 300 | 14.28 |
02:20 ET | 200 | 14.28 |
02:24 ET | 200 | 14.29 |
02:26 ET | 100 | 14.285 |
02:27 ET | 200 | 14.29 |
02:31 ET | 700 | 14.27 |
02:33 ET | 200 | 14.275 |
02:42 ET | 100 | 14.275 |
02:45 ET | 917 | 14.265 |
02:47 ET | 1300 | 14.27 |
02:49 ET | 935 | 14.21 |
02:51 ET | 600 | 14.225 |
02:54 ET | 400 | 14.2493 |
02:56 ET | 657 | 14.26 |
02:58 ET | 403 | 14.26 |
03:00 ET | 1000 | 14.25 |
03:02 ET | 1436 | 14.285 |
03:03 ET | 861 | 14.24 |
03:05 ET | 517 | 14.27 |
03:07 ET | 200 | 14.28 |
03:14 ET | 2317 | 14.3 |
03:16 ET | 1414 | 14.25 |
03:20 ET | 503 | 14.26 |
03:21 ET | 1657 | 14.205 |
03:23 ET | 400 | 14.19 |
03:25 ET | 3786 | 14.2 |
03:27 ET | 714 | 14.23 |
03:30 ET | 400 | 14.24 |
03:32 ET | 1708 | 14.22 |
03:34 ET | 1314 | 14.22 |
03:36 ET | 1509 | 14.23 |
03:38 ET | 2950 | 14.22 |
03:43 ET | 1502 | 14.2 |
03:48 ET | 2523 | 14.19 |
03:50 ET | 1800 | 14.19 |
03:52 ET | 2230 | 14.2 |
03:54 ET | 6687 | 14.235 |
03:56 ET | 5453 | 14.32 |
03:57 ET | 10277 | 14.29 |
03:59 ET | 100106 | 14.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Regenxbio Inc | 706.8M | -2.4x | --- |
SAGE Therapeutics Inc | 692.1M | -1.4x | --- |
WAVE Life Sciences Ltd | 755.6M | -12.0x | --- |
Zymeworks Inc | 596.0M | -4.7x | --- |
Y-mAbs Therapeutics Inc | 527.0M | -24.2x | --- |
Urogen Pharma Ltd | 489.6M | -4.0x | --- |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $706.8M |
---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 8.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.